Neovacs to present the pre-clinical results of its therapeutic vaccine candidate IL-4 / IL-13 Kinoid to treat allergic Asthma...
May 16 2019 - 1:30AM
Neovacs to present the pre-clinical results of its therapeutic
vaccine candidate IL-4 / IL-13 Kinoid to treat allergic Asthma
PRESS RELEASE ·
PRESS RELEASE ·
PRESS RELEASE
NEOVACS TO PRESENT THE PRE-CLINICAL
RESULTS OF ITS THERAPEUTIC VACCINE CANDIDATE IL-4
/ IL-13 KINOID TO TREAT ALLERGIC
ASTHMA
- « Antibodies and Complement 2019 » - Girona,
Spain- May 20-25, 2019
- « EAACI 2019 » - Lisbon,
Portugal, June 1-5 2019
Paris and Boston, May 16, 2019 –
Neovacs - 07h30 am CEST - (Euronext Growth Paris :
ALNEV), a leader in active immunotherapies for the
treatment of autoimmune diseases, today announced the presentation
of the pre-clinical results of its proof of concept in allergy with
its new IL-4 / IL-13 Kinoid therapeutic vaccine, at two majors
scientific congresses:
- « Antibodies and Complement
2019 » conference, in Girona, Spain
- May 20-25, 2019. This event will focus attention on key advances
in both fields: “Antibodies and Complement”.
- European Academy of Allergy and Clinical Immunology
Annual Congress 2019 “EAACI 2019”, to be
held in Lisbon, Portugal – June 1-5, 2019, under the theme:
“Mapping the new world of allergy (towards precision medicine in
allergy and asthma)”.
Eva Conde (Neovacs) and Dr. Laurent Reber from
the research team Inserm Unit 1222, Institut Pasteur, will present
during an oral session the results of this collaborative work. It
has been demonstrated in a representative allergic asthma model
that a treatment with IL-4 / IL-13 Kinoid enhanced the production
of polyclonal antibodies, which neutralize the two targeted
cytokines IL-4 and IL-13, both being development factors for
allergic asthma, thus avoiding the occurrance of any symptoms.
About Neovacs
Listed on Euronext Growth since 2010, Neovacs is
today a leading biotechnology company focused on an active
immunotherapy technology platform (Kinoids) with applications in
autoimmune and/or inflammatory diseases. On the basis of the
company’s proprietary technology for inducing a polyclonal immune
response (covered by four patent families that potentially run
until 2032) Neovacs is focusing its clinical development efforts on
IFNα-Kinoid, an immunotherapy being developed for the indication of
lupus, dermatomyositis and also in preclinical trial for Type 1
diabetes. Neovacs is also conducting preclinical development works
on other therapeutic vaccines in the fields of auto-immune
diseases, oncology and allergies. The goal of the Kinoid approach
is to enable patients to have access to safe treatments with
efficacy that is sustained in these life-long diseases.
www.neovacs.fr
Contacts
NEOVACS – Corporate Communication
& Investor RelationsCharlène
Masson+33 1 53 10 93 00cmasson@neovacs.com
NEWCAP- Media
Annie-Florence Loyer +33 1 44 71 00 12 / + 33
6 88 20 35 59afloyer@newcap.fr Léa Jacquin +33 1
44 71 20 41 / +33 6 58 14 84 66ljacquin@newcap.fr
ORPHEON FINANCE – Financial
Communication and Investor RelationsJames
Palmer +33 7 60 92 77 74j.palmer@orpheonfinance.com
- PR Neovacs present IL4IL13 MAY 2019-Finalversion
Neovacs (EU:ALNEV)
Historical Stock Chart
From Jun 2024 to Jul 2024
Neovacs (EU:ALNEV)
Historical Stock Chart
From Jul 2023 to Jul 2024